Guggenheim Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Guggenheim Capital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-19,364	Closed	-$910K	–	1663
2025 Q2	$910K	Buy	19,364 +1,335	+7%	+$59.4K	0.01%	925
2025 Q1	$796K	Sell	18,029 -2,100	-10%	-$96.7K	0.01%	973
2024 Q4	$727K	Sell	20,129 -4,855	-19%	-$170K	0.01%	1077
2024 Q3	$800K	Buy	24,984 +5,799	+30%	+$217K	0.01%	1196
2024 Q2	$723K	Buy	+19,185	New	+$807K	0.01%	1274
2022 Q2	–	Sell	-3,597	Closed	-$203K	–	2129
2022 Q1	$203K	Buy	3,597 +263	+8%	+$15.1K	﹤0.01%	2048
2021 Q4	$207K	Buy	+3,334	New	+$221K	﹤0.01%	2030

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Guggenheim Capital's SWTX Position: Q3 2025 in Review

Guggenheim Capital sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 19,364 shares — an estimated $910K sold.

Guggenheim Capital first reported a position in SWTX in Q4 2021 and held it in 7 quarters. The position peaked at $910K in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Guggenheim Capital reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Guggenheim Capital sold 19,364 SpringWorks Therapeutics shares in Q3 2025, an estimated $910K.
Guggenheim Capital first reported a position in SpringWorks Therapeutics in Q4 2021 and held it in 7 quarters.
Guggenheim Capital's SpringWorks Therapeutics position peaked at $910K in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Guggenheim Capital's 13F filing for Q3 2025, filed 13 Nov 2025.